http://www.89bio.com
89bio, Inc. Company Intro
89bio is a clinical-stage biopharmaceutical company focused on rapidly advancing our lead product candidate, BIO89-100, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH). BIO89-100 is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It may be a differentiated FGF21 therapy, and we believe it has the potential to become a mainstay of therapy for NASH given its ability to address the key liver pathologies (steatosis and fibrosis) and underlying metabolic dysregulation in patients with NASH. We are also expanding the breadth of indications for BIO89-100 with an initial focus on severe hypertriglyceridemia (SHTG).
Industry
Healthcare
89bio, Inc. Headquaters
142 Sansome Street
San Francisco,94104
United States
89bio, Inc. Share price
17 May 2023 13:09 GMT
$17.00
-0.87 (-4.87 %)
89bio, Inc. Market cap
$1.288 B
WMC RANKING
2024
89bio, Inc. # 470
BiotechnologyLatest 89bio, Inc. News
12 Feb 2024
Where Does 89bio Inc (ETNB) Stock Fall in the Biotechnology Field After It Is Down -7.86% This Week?
The 41 rating InvestorsObserver gives to 89bio Inc (ETNB) stock puts it near the middle of the Biotechnolog.
12 Feb 2024
Where Does 89bio Inc (ETNB) Stock Fall in the Biotechnology Field After It Is Down -7.86% This Week?
The 41 rating InvestorsObserver gives to 89bio Inc (ETNB) stock puts it near the middle of the Biotechnolog.
12 Feb 2024
Where Does 89bio Inc (ETNB) Stock Fall in the Biotechnology Field After It Is Down -7.86% This Week?
The 41 rating InvestorsObserver gives to 89bio Inc (ETNB) stock puts it near the middle of the Biotechnolog.
WMC Market Score
WMC Market to Revenue Score
89bio, Inc. Market Financials
Revenue, Expenses, Profit
| Company | Currency | Revenue | Expense | Profit | Market Cap | WMC Sector Score |
| 89bio, Inc. | USD | $0 | $53,392 | $-53,737 | $12,880B | 470 |
| Regeneron Pharmaceuticals, Inc. | USD | $9,197,600 | $3,997,800 | $4,003,800 | $804,390B | 1 |
| Vertex Pharmaceuticals Incorporated | USD | $6,414,881 | $2,617,257 | $2,762,032 | $878,880B | 2 |
| Alexion Pharmaceuticals, Inc. | USD | $6,261,601 | $2,747,200 | $681,800 | $ 0.00 | 3 |
| ALK-Abello A/S | USD | $3,556,000 | $1,893,000 | $66,000 | $189,400B | 4 |
Market Analytics
Company Search vs Top 4 Industry Competitors
Total 89bio, Inc. Social Followers vs Top 4 Industry Competitors
89bio, Inc. Post vs Top 4 Industry Competitors
89bio, Inc. Digital Footprint By Size vs Top 4 Industry Competitors
89bio, Inc. Digital Footprint By Change Rate vs Top 4 Industry Competitors
89bio, Inc. WMC Market Score Calculations
| Details | Revenue | Total Social Followers | Total Social Posts | Search Volume | Digital Footprint Size | Digital change (New Pages) | WMC Market Score |
| 89bio, Inc. | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Regeneron Pharmaceuticals, Inc. | 100 | 25.50 | 16.15 | 70 | 0 | 0 | 39.85 |
| Vertex Pharmaceuticals Incorporated | 69.75 | 35.68 | 8.95 | 100 | 0 | 0 | 51.56 |
| Alexion Pharmaceuticals, Inc. | 68.08 | 100 | 100 | 80 | 0 | 0 | 100 |
| ALK-Abello A/S | 38.66 | 0 | 0 | 0 | 0 | 0 | 0 |
Book a demo
Book a free one-on-one demo with one of our team and see exactly how the WMC business intelligence platform can help you protect and grow revenue.
* required fields
You'll learn how to:
- 1. Automatically monitor your entire digital landscape including competitors
- 2. View all new industry activity in real time
- 3. Monitor your position in your industry
- 4. Enrich your reports and strategy
- 5. Empower your teams with knowledge
